Opioid-Related Disorders Clinical Trial
Official title:
The Therapeutic Workplace Initiation Study
Verified date | December 2017 |
Source | Johns Hopkins University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The primary purpose of the study is to determine if the central feature of the Therapeutic Workplace, the abstinence reinforcement contingency, is critical to initiate cocaine abstinence in injection drug using methadone patients who use cocaine consistently during methadone treatment. All subjects initially will be invited to attend the Therapeutic Workplace for an initial period, but abstinence will not be required to work during that time. During this initial period, vouchers will be contingent only on workplace attendance and performance on the training programs. Subjects (n=70) who attend the workplace consistently during the first 4 weeks of treatment, but who continue to use cocaine will be randomly assigned to a Work Only or an Abstinence Plus Work group. Subjects in the Work Only group will continue to be able to work independent of their urinalysis results. However, subjects in the Abstinence Plus Work group will be required to provide urine samples that show evidence of recent cocaine abstinence. Subjects in both groups will be invited to stay in the workplace for 6 months. We expect the subjects in the Abstinence and Work group will achieve higher rates of abstinence than the subjects in the Work Only group. This result would show that the abstinence reinforcement contingency (i.e., the requirement to provide cocaine-free urine samples to work and earn vouchers) is important in the initiation of abstinence in the study population.
Status | Completed |
Enrollment | 117 |
Est. completion date | October 2004 |
Est. primary completion date | May 2004 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Baseline inclusion criteria: - are at least 18 years of age - are enrolled in methadone maintenance treatment in Baltimore - provide a cocaine-positive urine sample at time of initial screening - self-report cocaine use through intravenous route - have visible evidence of intravenous drug use (i.e., track marks). Baseline exclusion criteria: - report current suicidal ideation - if the individual reports hallucinations - have physical limitations (e.g., broken fingers) that prevent the subject from typing. - Applicants reporting hallucinations are excluded because this is a characteristic of a psychiatric disorder that is likely to result in behaviors that could disrupt the workplace or functioning or limit their ability to provide informed consent. Main study inclusion criteria: - have attended the workplace regularly during 4-week baseline periods - are still in methadone maintenance treatment at the end of the 4-week baseline period - have provided at least two urine samples that test positive for cocaine during the baseline period - Individuals who are excluded from the main study will be allowed to complete their 8-week training program in the Therapeutic Workplace. They may also be invited to participate in other studies ongoing at the Center for Learning and Health where this research takes place. |
Country | Name | City | State |
---|---|---|---|
United States | The Center for Learning and Health | Baltimore | Maryland |
Lead Sponsor | Collaborator |
---|---|
Johns Hopkins University | National Institute on Drug Abuse (NIDA) |
United States,
Silverman K, Wong CJ, Needham M, Diemer KN, Knealing T, Crone-Todd D, Fingerhood M, Nuzzo P, Kolodner K. A randomized trial of employment-based reinforcement of cocaine abstinence in injection drug users. J Appl Behav Anal. 2007 Fall;40(3):387-410. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Cocaine Abstinence | Percentage of Monday, Wednesday, Friday urine samples that are negative for cocaine | 6 months | |
Secondary | Percent Opiate Negative | (total number of opiate-negative urine samples divided by the total number of urine samples provided)*100 | every month for 6 months | |
Secondary | HIV Risk Behaviors | Report no injection drug use or crack cocaine use. | every month for 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03950492 -
Feasibility of Deep Brain Stimulation as a Novel Treatment for Refractory Opioid Use Disorder
|
N/A | |
Completed |
NCT00000335 -
Activity Monitoring Assessment of Opiate Withdrawal - 4
|
Phase 2 | |
Active, not recruiting |
NCT03949764 -
The Kentucky Viral Hepatitis Treatment Study
|
Phase 4 | |
Enrolling by invitation |
NCT06084221 -
Fatal Overdose Review Teams - Research to Enhance Surveillance Systems
|
N/A | |
Completed |
NCT02978417 -
Feasibility Study of Extended-release Naltrexone (Vivitrol) in Drug Court Settings
|
Phase 4 | |
Withdrawn |
NCT03137030 -
A Comparison of Plasma Concentrations of Hydrocodone and Acetaminophen After Administration of Different Amounts of Tablets of a New and a Marketed Tablet Formulation in Healthy Adults
|
Phase 1 | |
Withdrawn |
NCT03137017 -
A Comparison of Plasma Concentrations of Hydrocodone and Acetaminophen After Administration of a New and a Marketed Tablet Formulation Under Fasted and Fed Conditions in Healthy Adults
|
Phase 1 | |
Completed |
NCT02282306 -
Phone Interview to Prevent Recurring Opioid Overdoses
|
N/A | |
Completed |
NCT00710385 -
Abuse Liability of Suboxone Versus Subutex
|
Phase 3 | |
Completed |
NCT00142935 -
Effectiveness of Opiate Replacement Therapy Administered Prior to Release From a Correctional Facility - 1
|
N/A | |
Completed |
NCT00218309 -
Effects of Pre-Session Supplemental Hydromorphone on Drug Seeking Behavior in Opioid Dependent Individuals
|
Phase 2 | |
Terminated |
NCT00000243 -
Effects of Buprenorphine/Naloxone in Treating Opioid Dependent Individuals Who Are Maintained on Methadone
|
N/A | |
Completed |
NCT00067184 -
Fetal Neurobehavioral Development in Methadone Maintained Pregnancies
|
||
Completed |
NCT00000264 -
Subjective/Psychomotor/ Effects of Combined Alcohol & Nitrous Oxide - 16
|
N/A | |
Completed |
NCT00000257 -
Effects of Alcohol History on Effects of Nitrous Oxide - 9
|
N/A | |
Completed |
NCT00000279 -
Novel Medications for Opiate Detoxification - 4
|
Phase 2 | |
Completed |
NCT00000306 -
Dextroamphetamine as Adjunct in Cocaine/Opiate Dependent Patients - 3
|
Phase 2 | |
Completed |
NCT00000249 -
Effects of Subanesthetic Concentrations of Nitrous Oxide - 1
|
Phase 2 | |
Recruiting |
NCT04933084 -
Pre-operative Education Modalities to Decrease Opioid Use
|
N/A | |
Recruiting |
NCT03610672 -
Mobile Intervention for Young Opioid Users
|
N/A |